Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C128H194N40O28S2 |
| Molecular Weight | 2805.2983 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 22 / 22 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C[C@H](NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CS[C@@H]2CC(=O)N(CCCCCCN3C(=O)C[C@H](SC[C@H](NC(=O)[C@H](CC4=CC=CC=C4)NC(=O)CNC(=O)[C@@H]5C[C@@H](O)CN5C(=O)[C@@H]6CCCN6C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@H](CC7=CC=CC=C7)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C3=O)C2=O)NC(=O)[C@H](CC8=CC=CC=C8)NC(=O)CNC(=O)[C@@H]9C[C@@H](O)CN9C(=O)[C@@H]%10CCCN%10C(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](N)CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O
InChI
InChIKey=JKUYFMHGTOPVMR-WQVVEKGHSA-N
InChI=1S/C128H194N40O28S2/c1-71(2)55-85(105(177)155-83(121(193)194)41-25-49-147-127(139)140)157-109(181)89(59-75-33-15-9-16-34-75)159-111(183)91(161-107(179)87(57-73-29-11-7-12-30-73)151-99(171)65-149-113(185)95-61-77(169)67-167(95)117(189)93-43-27-53-163(93)115(187)81(39-23-47-145-125(135)136)153-103(175)79(129)37-21-45-143-123(131)132)69-197-97-63-101(173)165(119(97)191)51-19-5-6-20-52-166-102(174)64-98(120(166)192)198-70-92(112(184)160-90(60-76-35-17-10-18-36-76)110(182)158-86(56-72(3)4)106(178)156-84(122(195)196)42-26-50-148-128(141)142)162-108(180)88(58-74-31-13-8-14-32-74)152-100(172)66-150-114(186)96-62-78(170)68-168(96)118(190)94-44-28-54-164(94)116(188)82(40-24-48-146-126(137)138)154-104(176)80(130)38-22-46-144-124(133)134/h7-18,29-36,71-72,77-98,169-170H,5-6,19-28,37-70,129-130H2,1-4H3,(H,149,185)(H,150,186)(H,151,171)(H,152,172)(H,153,175)(H,154,176)(H,155,177)(H,156,178)(H,157,181)(H,158,182)(H,159,183)(H,160,184)(H,161,179)(H,162,180)(H,193,194)(H,195,196)(H4,131,132,143)(H4,133,134,144)(H4,135,136,145)(H4,137,138,146)(H4,139,140,147)(H4,141,142,148)/t77-,78-,79-,80-,81+,82+,83+,84+,85+,86+,87+,88+,89-,90-,91+,92+,93+,94+,95+,96+,97-,98+/m1/s1
| Molecular Formula | C128H194N40O28S2 |
| Molecular Weight | 2805.2983 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 22 / 22 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Deltibant is the bradykinin receptor antagonist. It was found to be a potent and selective inhibitor of the depressor response to bradykinin in the anaesthetized rat and rabbit. Deltibant affords significant protection against traumatic shock where bradykinin plays an important role in tissue injury. Such protection may be achieved through inhibition of neutrophil-endothelial interaction and protection of vascular endothelial function. Deltibant may have some effect on survival in patients with systemic inflammatory response syndrome and gram-negative sepsis. Kinin-kallikrein system could be involved in cerebral edema - treatment with deltibant appeared to alter the natural history of traumatic brain contusions by preventing the 2 degrees brain swelling. In addition, deltibant obviated the need for surgery in the majority of treated patients. Deltibant could act on the cerebral vasculature to limit dys-autoregulation and brain swelling or on the blood brain barrier to reduce cerebral edema. Deltibant has been in phase II clinical trials for the treatment of pain, immune-inflammatory diseases and stroke. However, this research has been discontinued.
Approval Year
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/9020273
Three-day continuous infusion 1 of 3 doses (0.3, 1.0, or 3.0 ug/kg/min)
Route of Administration:
Intravenous
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 20:50:24 GMT 2025
by
admin
on
Mon Mar 31 20:50:24 GMT 2025
|
| Record UNII |
6151J4V7VX
|
| Record Status |
FAILED
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
7484
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
140661-97-8
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
70697628
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
C071326
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
SUB06960MIG
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
6151J4V7VX
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
C166885
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
CHEMBL2103953
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
207511-94-2
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
NON-SPECIFIC STEREOCHEMISTRY | |||
|
100000083689
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | |||
|
m1037
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY | Merck Index | ||
|
HH-11
Created by
admin on Mon Mar 31 20:50:24 GMT 2025 , Edited by admin on Mon Mar 31 20:50:24 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
||
|
TARGET -> INHIBITOR |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|